Loading...
OTCM
RHYBF
Market cap22mUSD
, Last price  
USD
Name

Rhythm Biosciences Ltd

Chart & Performance

D1W1MN
OTCM:RHYBF chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.95%
Rev. gr., 5y
99.90%
Revenues
3m
+88.87%
001,028,000100,0001,109,0002,427,0003,096,0001,690,0003,191,913
Net income
-4m
L-44.15%
-72,127-1,753,000-2,546,000-4,023,000-6,612,000-8,794,000-8,218,000-6,857,000-3,829,371
CFO
-3m
L-52.40%
0-1,651,299-2,941,596-2,742,598-5,402,486-6,214,705-6,957,610-6,137,171-2,921,287

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.
URL
https://www.rhythmbio.com/
IPO date
Dec 07, 2017
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑082017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT